



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/957,056	09/20/2001	Mark L. Tykocinski	285332-00002-2	6690
3705	7590	02/13/2004	EXAMINER	
ECKERT SEAMANS CHERIN & MELLOTT			HARRIS, ALANA M	
600 GRANT STREET			ART UNIT	PAPER NUMBER
44TH FLOOR				1642
PITTSBURGH, PA 15219				

DATE MAILED: 02/13/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/957,056	TYKOCINSKI ET AL.	
	Examiner	Art Unit	
	Alana M. Harris, Ph.D.	1642	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on November 18, 2003.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 23 and 51-61 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 23 and 51-61 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____. |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____. | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| | 6) <input type="checkbox"/> Other: _____. |

DETAILED ACTION

1. Claims 23 and 51-61 are pending.
Claims 23, 51-54 and 60 have been amended.
Claims 23 and 51-61 are examined on the merits.

Withdrawn Rejection

Claim Rejections - 35 USC § 103

2. The rejection of claims 23 and 51-61 under 35 U.S.C. 103(a) as being unpatentable over Kim and Peacock (Journal of Immunological Methods 158:57-65, 1993/ Document J on IDS) in view of Brunschwig et al. (Journal of Immunology 155:5498-5505, 1995/Document G on IDS) is withdrawn in light of Applicants' arguments and declaration.

New Grounds of Objection

Specification

3. The disclosure is objected to because of the following informality: on page 13, line 14 it is not clear what the recitation [???] means.
Correction is required.

New Grounds of Rejection***Claim Rejections - 35 USC § 112***

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 23 and 51-61 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The written description in this case only sets forth three cells with a defined lipidated protein and defined fusion proteins, which are to be implemented in Applicants' methods. These cells are exemplified in Example 1 (pages 9-12), Example 3 (pages 17 and 18) and Example 6 (pages 19 and 20). Example 1 provides K562 cell with a lipidated protein, palmitated protein A (pal-prot A) bound to a fusion protein, B7-1.Fc γ 1, wherein B7-1 is a second domain type I costimulator and Fc γ 1 the first domain of the fusion protein. Example 3 exemplifies the T-50 cell having a pal-prot A bound to a complex of costimulator fusion proteins, mB7-1 (type I), m4=1BBL.Fc and hCD40L.Fc (both type II). And Example 6 provides a CHO cell with a Fc-hFasL coinhibitor fusion protein and pal-prot A. The written description in this is limited to the three aforementioned cell types and not any cell with the broadly described features.

Vas-Cath Inc. V. Mahurkar, 19 USPQ2d 1111, clearly states that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought,

he or she was in possession of *the invention*. The invention is, for purposes of the ‘written description’ inquiry, *whatever is now claimed.*” (See page 1117). The specification does not “clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed.” (See *Vas-Cath* at page 1116). Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 USC 112 is severable from its enablement provision (see page 115).

Applicants are not required to disclose every species encompassed by a genus. For example as indicated in *The Regents of the University of California v. Eli Lilly* (43 USPQ2d 1398-1412), the description of a genus is achieved by the recitation of a representative number of DNA molecules, usually defined by a nucleotide sequence, falling within the scope of the claimed genus. At section B(1), the court states that “An adequate written description of a DNA...’requires a precise definition, such as by structure, formula, chemical name, or physical properties’, not a mere wish or plan for obtaining the claimed chemical invention”.

Applicants broadly claim, “[a] cell having a lipidated protein incorporated into the cell membrane, said lipidated protein having bound thereto a fusion protein, said fusion protein comprising a first domain and a second domain having a trans signaling and/or adhesion function”. This claim reads on a multitude of cells comprising numerous proteins and protein derivatives, which are supposed to carry out several functions as set forth by the claim language. Applicants are not entitled, nor is the specification enabled for the use of all costimulators/coinhibitors as a second domain of the fusion protein and any protein/protein derivatives as a first domain of the said fusion protein.

Art Unit: 1642

Applicants are not entitled, nor is the specification enabled for the use of all the cells that the wide breadth of claim 23 encompasses. Applicants are in possession of three species. Applicants are not permitted to claim all types of cells as embraced by the claims, specifically claim 23. Hence Applicants are not entitled to the wide breadth of the claims at issue. There is no disclosure beyond the mention of the three cell types of Examples 1, 3 and 6 is made in the specification. As Applicants' claims are written the cell could include countless numbers of proteins.

This is insufficient to support the generic claims as provided by the Interim Written Description Guidelines published in the June 15, 1998 Federal Register at Volume 63, Number 114, pages 32639-32645.

6. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

7. Claims 23 and 51-61 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

a. Claim 23 is vague and indefinite in the recitation "*trans* signaling" and "adhesion function". It is not clear from the claims what activities these recitations read on. Accordingly, the metes and bounds cannot be determined.

Conclusion

8. Claims 23 and 51-61 are free of the art.

Art Unit: 1642

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alana M. Harris, Ph.D. whose telephone number is (703) 306-5880. The examiner can normally be reached on 7:00 am to 4:30 pm, with alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne "Bonnie" Eyler, Ph.D. can be reached on (703) 308-6564. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

ALANA M. HARRIS, PH.D.

PRIMARY EXAMINER



Alana M. Harris, Ph.D.
05 February 2004